Key insights
- The FDA granted Priority Review to J&J's IMAAVY for warm autoimmune hemolytic anemia, potentially offering a significant treatment improvement. This positive regulatory development could modestly boost investor sentiment towards JNJ, reflecting potential revenue growth in a niche market. However, the overall impact on JNJ's vast portfolio is limited.
SPRING HOUSE, Pa. - Johnson & Johnson (NYSE:JNJ) announced today that the U.S. Food and Drug Administration has granted Priority Review to the supplemental Biologics License Application for IMAAVY (nipocalimab-aahu) for the treatment of warm autoimmune hemolytic anemia.
Priority Review shortens the FDA review timeline to approximately six months and is granted to medicines that may offer significant improvements in safety or effectiveness for serious conditions. IMAAVY is the first therapy to receive FDA Priority Review for this condition, according to a press release statement.
Warm autoimmune hemolytic anemia is a rare, life-threatening condition where immunoglobulin G autoantibodies attach to and destroy red blood cells, resulting in anemia. Approximately 1-3 new people per 100,000 are affected by the condition per year. There are currently no FDA-approved drugs indicated for warm autoimmune hemolytic anemia, with treatment typically consisting of unapproved corticosteroids and broad immunosuppressants.
IMAAVY is designed to block the neonatal Fc receptor, reducing circulating immunoglobulin G, including pathogenic autoantibodies, while preserving key immune functions. The drug is currently approved for the treatment of generalized myasthenia gravis in adults and pediatric patients 12 years of age and older who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive.
The FDA’s decision is supported by results from the pivotal Phase 2/3 ENERGY study, which showed that more patients treated with IMAAVY achieved a durable hemoglobin response compared with placebo, along with improvements in fatigue. The full results of the ENERGY trial will be presented at an upcoming medical conference.
The legal manufacturer for IMAAVY is Janssen Biotech, Inc., a Johnson & Johnson company.
In other recent news, Johnson & Johnson announced that the U.S. Food and Drug Administration granted Priority Review to its supplemental biologics license application for IMAAVY as a treatment for warm autoimmune hemolytic anemia. This marks the first time a therapy for this condition has received such expedited review, potentially shortening the approval timeline to approximately six months. In another development, Johnson & Johnson has entered into a definitive agreement to acquire Atraverse Medical, a company specializing in medical devices, including the HOTWIRE Transseptal Access System for atrial fibrillation procedures.
Additionally, Johnson & Johnson shared new data from its Phase 3 study indicating sustained clinical improvements with IMAAVY in treating generalized myasthenia gravis over 120 weeks. The company also introduced the CARTOSOUND SONATA Module, an AI-powered cardiac mapping technology, at the Heart Rhythm Society Annual Meeting. On the financial front, Freedom Broker raised its price target for Johnson & Johnson to $230, citing a strong quarterly performance that exceeded expectations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.